KR20240068737A - Glp-1r 효능제로서의 벤즈이미다졸 카복실산 - Google Patents
Glp-1r 효능제로서의 벤즈이미다졸 카복실산 Download PDFInfo
- Publication number
- KR20240068737A KR20240068737A KR1020247014116A KR20247014116A KR20240068737A KR 20240068737 A KR20240068737 A KR 20240068737A KR 1020247014116 A KR1020247014116 A KR 1020247014116A KR 20247014116 A KR20247014116 A KR 20247014116A KR 20240068737 A KR20240068737 A KR 20240068737A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- optionally substituted
- alkyl
- ring
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163261717P | 2021-09-27 | 2021-09-27 | |
| US63/261,717 | 2021-09-27 | ||
| PCT/US2022/044915 WO2023049518A1 (en) | 2021-09-27 | 2022-09-27 | Benzimidazole carboxylic acids as glp-1r agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240068737A true KR20240068737A (ko) | 2024-05-17 |
Family
ID=83899713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247014116A Withdrawn KR20240068737A (ko) | 2021-09-27 | 2022-09-27 | Glp-1r 효능제로서의 벤즈이미다졸 카복실산 |
Country Status (25)
| Country | Link |
|---|---|
| US (7) | US20230150998A1 (https=) |
| EP (2) | EP4408840B1 (https=) |
| JP (1) | JP2024534621A (https=) |
| KR (1) | KR20240068737A (https=) |
| CN (1) | CN118251391A (https=) |
| AU (1) | AU2022349020A1 (https=) |
| CA (1) | CA3233201A1 (https=) |
| CL (1) | CL2024000861A1 (https=) |
| CO (1) | CO2024005060A2 (https=) |
| DK (1) | DK4408840T3 (https=) |
| ES (1) | ES3049198T3 (https=) |
| FI (1) | FI4408840T3 (https=) |
| HR (1) | HRP20251161T1 (https=) |
| HU (1) | HUE073500T2 (https=) |
| IL (1) | IL311667A (https=) |
| LT (1) | LT4408840T (https=) |
| MX (1) | MX2024003872A (https=) |
| PE (1) | PE20241130A1 (https=) |
| PL (1) | PL4408840T3 (https=) |
| PT (1) | PT4408840T (https=) |
| RS (1) | RS67271B1 (https=) |
| SI (1) | SI4408840T1 (https=) |
| SM (1) | SMT202500374T1 (https=) |
| TW (1) | TW202322806A (https=) |
| WO (1) | WO2023049518A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT4408840T (pt) | 2021-09-27 | 2025-10-07 | Terns Pharmaceuticals Inc | Ácidos benzimidazolocarboxílicos como agonistas de glp-1r |
| CN118401519A (zh) | 2021-10-25 | 2024-07-26 | 拓臻制药公司 | 作为glp-1r激动剂的化合物 |
| CN119095843A (zh) | 2022-02-23 | 2024-12-06 | 拓臻制药公司 | 作为glp-1r激动剂的化合物 |
| WO2024051700A1 (zh) * | 2022-09-05 | 2024-03-14 | 德睿智药(苏州)新药研发有限公司 | 作为glp1r激动剂的新型芳基氘代苄醚取代杂环类化合物 |
| TW202504595A (zh) * | 2023-03-29 | 2025-02-01 | 美商拓臻製藥公司 | Ｇｌｐ—１ｒ促效劑之多晶型及鹽 |
| EP4568664B1 (en) | 2023-04-07 | 2026-04-01 | Terns Pharmaceuticals, Inc. | Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity |
| WO2024212742A1 (zh) * | 2023-04-10 | 2024-10-17 | 上海研健新药研发有限公司 | 一种glp-1r激动剂，其制备方法和应用 |
| CN120981457A (zh) | 2023-09-14 | 2025-11-18 | 歌礼制药(中国)有限公司 | Glp-1r激动剂及其治疗方法 |
| TW202521534A (zh) | 2023-11-24 | 2025-06-01 | 香港商歌禮製藥(中國)有限公司 | Glp-1r 激動劑及其治療方法 |
| WO2025158275A1 (en) | 2024-01-24 | 2025-07-31 | Pfizer Inc. | Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds |
| TW202600132A (zh) | 2024-03-08 | 2026-01-01 | 美商安尼波那生物公司 | 用於治療肥胖症及提高減重之方法 |
Family Cites Families (118)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9305641D0 (en) | 1993-03-18 | 1993-05-05 | Merck Sharp & Dohme | Therapeutic agents |
| US5714498A (en) | 1993-03-18 | 1998-02-03 | Merck, Sharp, & Dohme, Ltd. | Benzimidazole derivatives |
| GB9305623D0 (en) | 1993-03-18 | 1993-05-05 | Merck Sharp & Dohme | Therapeutic agents |
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| US6960589B2 (en) | 2001-03-09 | 2005-11-01 | Abbott Laboratories | Benzimidazoles that are useful in treating sexual dysfunction |
| ATE369854T1 (de) | 2001-10-19 | 2007-09-15 | Ortho Mcneil Pharm Inc | 2-phenyl benzimidazole und imidazo-[4,5]-pyridine als cds1/chk2-inhibitoren und adjuvantien in der chemotherapie oder strahlungstherapie zur behandlung von krebs |
| US20040127504A1 (en) | 2002-09-06 | 2004-07-01 | Cowart Marlon D. | Benzimidazoles that are useful in treating sexual dysfunction |
| US7329680B2 (en) | 2003-04-30 | 2008-02-12 | The Institute For Pharmaceutical Discovery, Llc | Heterocycle substituted carboxylic acids |
| PL2007752T3 (pl) | 2006-03-31 | 2011-02-28 | Janssen Pharmaceutica Nv | Benzoimidazol-2-ilopirymidyny i pirazyny jako modulatory receptora histaminowego H4 |
| WO2008012623A1 (en) | 2006-07-25 | 2008-01-31 | Pfizer Products Inc. | Benzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor |
| MY159575A (en) | 2009-04-02 | 2017-01-13 | Merck Serono Sa | Dihydroorotate dehydrogenase inhibitors |
| WO2010114957A1 (en) | 2009-04-03 | 2010-10-07 | Schering Corporation | Bicyclic piperidine and piperazine derivatives as gpcr modulators for the treatment of obesity, diabetes and other metabolic disorders |
| WO2011143365A1 (en) | 2010-05-13 | 2011-11-17 | Amgen Inc. | Nitrogen heterocyclic compounds useful as pde10 inhibitors |
| EP2866825B1 (en) | 2012-07-01 | 2020-04-08 | Novo Nordisk A/S | Use of long-acting glp-1 peptides |
| WO2015166398A1 (en) | 2014-04-30 | 2015-11-05 | Aurigene Discovery Technologies Limited | 3h-imidazo[4,5-b]pyridine derivatives as dihydroorotate dehydrogenase inhibitors |
| JOP20190060A1 (ar) | 2016-09-26 | 2019-03-26 | Chugai Pharmaceutical Co Ltd | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
| KR102314286B1 (ko) | 2016-12-16 | 2021-10-21 | 화이자 인코포레이티드 | Glp-1 수용체 작용제 및 이의 용도 |
| JP7461104B2 (ja) | 2017-11-29 | 2024-04-03 | 中外製薬株式会社 | Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物 |
| US10934279B2 (en) * | 2018-06-13 | 2021-03-02 | Pfizer Inc. | GLP-1 receptor agonists and uses thereof |
| DK3806855T5 (da) | 2018-06-15 | 2023-05-22 | Pfizer | GLP-1-receptoragonister og anvendelser deraf |
| TWI705820B (zh) | 2018-06-22 | 2020-10-01 | 美商美國禮來大藥廠 | Gip/glp1促效劑組合物 |
| US11254660B2 (en) | 2018-08-31 | 2022-02-22 | Pfizer Inc. | Combinations for treatment of NASH/NAFLD and related diseases |
| MA54555A (fr) | 2018-11-22 | 2021-09-29 | Qilu Regor Therapeutics Inc | Agonistes de glp-1r et leurs utilisations |
| CN113365637A (zh) | 2018-12-05 | 2021-09-07 | 维京治疗公司 | 用于治疗肝部病症的组合物和方法 |
| EP3953344A4 (en) | 2019-04-12 | 2023-08-09 | Qilu Regor Therapeutics Inc. | GLP-IR AGONISTS AND THEIR USES |
| TWI751585B (zh) | 2019-06-28 | 2022-01-01 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| WO2021018023A1 (zh) | 2019-08-01 | 2021-02-04 | 济南泰达领创医药技术有限公司 | 小分子glp-1受体调节剂 |
| EP4048664A1 (en) * | 2019-10-25 | 2022-08-31 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| KR20210059584A (ko) | 2019-11-15 | 2021-05-25 | 일동제약(주) | Glp-1 수용체 작용제 및 이의 용도 |
| WO2021096284A1 (ko) | 2019-11-15 | 2021-05-20 | 일동제약(주) | Glp-1 수용체 작용제 및 이의 용도 |
| CN114761395B (zh) * | 2019-12-02 | 2024-11-15 | 现代药品株式会社 | Glp-1受体激动剂 |
| KR20220112811A (ko) | 2019-12-10 | 2022-08-11 | 화이자 인코포레이티드 | 2-((4-((S)-2-(5-클로로피리딘-2-일)-2-메틸벤조[d][1,3]디옥솔-4-일)피페리딘-1-일)메틸)-1-(((S)-옥세탄-2-일)메틸)-1H-벤조[d]이미다졸-6-카르복실산, 1,3-디히드록시-2-(히드록시메틸)프로판-2-아민 염의 고체 형태 |
| ES3016132T3 (en) | 2020-01-29 | 2025-05-08 | Gilead Sciences Inc | Glp-1r modulating compounds |
| HRP20241159T1 (hr) | 2020-02-07 | 2024-12-06 | Gasherbrum Bio, Inc. | Heterociklički agonisti za glp-1 |
| JP7836762B2 (ja) | 2020-02-13 | 2026-03-27 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環ｇｌｐ－１アゴニスト |
| IL296336A (en) | 2020-03-18 | 2022-11-01 | Lg Chemical Ltd | Glp-1 receptor agonist, pharmaceutical composition comprising same, and method for preparing same |
| CN113493447B (zh) | 2020-04-03 | 2024-06-11 | 轩竹(北京)医药科技有限公司 | Glp-1受体激动剂 |
| TW202144340A (zh) | 2020-04-03 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用 |
| TW202206429A (zh) | 2020-04-29 | 2022-02-16 | 美商迦舒布魯姆生物有限公司 | 雜環ｇｌｐ—１促效劑 |
| JP7702973B2 (ja) | 2020-05-27 | 2025-07-04 | キル・レガー・セラピューティクス・インコーポレーテッド | Ｇｌｐ－１ｒアゴニストの塩及び結晶形態、並びにそれらの使用 |
| CN111548311B (zh) | 2020-06-04 | 2021-04-23 | 山西医科大学 | 一种小分子glp-1r激动剂及其应用 |
| MX2022015026A (es) | 2020-06-04 | 2023-01-04 | Hangzhou Sciwind Biosciences Co Ltd | Compuesto heteroaromatico de imidazol de cinco miembros y uso del mismo. |
| CN115697338B (zh) | 2020-06-10 | 2024-08-09 | 东宝紫星(杭州)生物医药有限公司 | 甲基取代的苯并二噁唑类化合物及其应用 |
| CN115916772B (zh) | 2020-06-19 | 2025-01-14 | 江苏恒瑞医药股份有限公司 | 6-氧代-3,6-二氢吡啶类衍生物、其制备方法及其在医药上的应用 |
| CN113831337B (zh) | 2020-06-24 | 2023-03-24 | 广州市恒诺康医药科技有限公司 | Glp-1受体激动剂及其药物组合物和用途 |
| US12037339B2 (en) | 2020-07-20 | 2024-07-16 | Eccogene Inc. | Substituted imidazoles as GLP-1 receptor agonists |
| JP2023537501A (ja) | 2020-08-06 | 2023-09-01 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環ｇｌｐ－１アゴニスト |
| WO2022031994A1 (en) | 2020-08-06 | 2022-02-10 | Qilu Regor Therapeutics Inc. | Glp-1r agonists and uses thereof |
| CA3192601A1 (en) | 2020-08-21 | 2022-02-24 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| EP4204415A4 (en) | 2020-08-28 | 2025-03-26 | Gasherbrum Bio, Inc. | HETEROCYCLIC GLP-1 AGONISTS |
| CA3188891A1 (en) | 2020-09-01 | 2022-01-13 | Fanglong Yang | Fused imidazole derivative, preparation method therefor, and medical use thereof |
| EP4211133A4 (en) | 2020-09-07 | 2024-11-27 | Gasherbrum Bio, Inc. | HETEROCYCLIC GLP-1 AGONISTS |
| CN116368140A (zh) | 2020-09-10 | 2023-06-30 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| WO2022068772A1 (zh) | 2020-09-29 | 2022-04-07 | 深圳信立泰药业股份有限公司 | 一种苯并咪唑类衍生物及其制备方法和医药用途 |
| WO2022078152A1 (zh) | 2020-10-12 | 2022-04-21 | 杭州中美华东制药有限公司 | 苯并咪唑酮类glp-1受体激动剂及其用途 |
| EP4229050A4 (en) | 2020-10-13 | 2024-12-11 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| US20240083886A1 (en) | 2020-10-13 | 2024-03-14 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| CN116710446B (zh) | 2020-10-14 | 2024-10-18 | 上海齐鲁锐格医药研发有限公司 | Glp-1r激动剂的晶型及其用途 |
| EP4247804A1 (en) | 2020-11-20 | 2023-09-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
| MX2023006186A (es) | 2020-11-27 | 2023-08-07 | Shenzhen Salubris Pharm Co Ltd | Derivado de benzimidazol y método de preparación del mismo y uso médico del mismo. |
| CN114591308B (zh) | 2020-12-03 | 2024-03-08 | 苏州闻泰医药科技有限公司 | 一类glp-1r受体激动剂化合物及其用途 |
| WO2022135572A1 (zh) | 2020-12-25 | 2022-06-30 | 四川海思科制药有限公司 | 一种五并五元环衍生物及其在医药上的应用 |
| CR20230330A (es) | 2021-01-28 | 2023-11-15 | Carmot Therapeutics Inc | Agonistas del receptor gpcr, composiciones farmaceuticas que los comprenden y métodos para su uso |
| EP4304712A1 (en) | 2021-03-11 | 2024-01-17 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| WO2022192428A1 (en) | 2021-03-11 | 2022-09-15 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| US20240208952A1 (en) | 2021-03-22 | 2024-06-27 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | Thiophene glp-1 receptor agonist and use thereof |
| CN117222631A (zh) | 2021-03-24 | 2023-12-12 | 诚益生物(美国)公司 | 苯基-[1,3]二氧杂环戊烯并[4,5-c]吡啶基-苯基-、苯基-[1,3]二氧杂环戊烯并[4,5-c]吡啶基-杂芳基-或苯基-[1,3]二氧杂环戊烯并[4,5-c]吡啶基-哌啶基-甲基-氧杂环丁烷基甲基-1h-苯并[d]咪唑-甲酸衍生物及其使用方法 |
| JP7772778B2 (ja) | 2021-03-24 | 2025-11-18 | 塩野義製薬株式会社 | 縮合環を有するｇｌｐ－１受容体作動薬を含有する医薬組成物 |
| ES2925124B2 (es) | 2021-03-29 | 2024-04-08 | Fundacion Univ San Antonio | Tratamiento de la obesidad |
| WO2022216094A1 (ko) | 2021-04-08 | 2022-10-13 | 주식회사 엘지화학 | Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법 |
| WO2022219495A1 (en) | 2021-04-12 | 2022-10-20 | Novartis Ag | 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity |
| IL306110A (en) | 2021-04-21 | 2023-11-01 | Gilead Sciences Inc | Carboxy-benzimidazole glp-1r modulating compounds |
| CN117177970A (zh) | 2021-04-30 | 2023-12-05 | 上海翰森生物医药科技有限公司 | 多环类衍生物调节剂、其制备方法和应用 |
| EP4334304A1 (en) | 2021-05-03 | 2024-03-13 | Carmot Therapeutics, Inc. | Benzimidazoyl glp-1 receptor agonists, pharmaceutical compositions comprising the same, and methods for their use |
| TWI843104B (zh) | 2021-05-20 | 2024-05-21 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| CA3221661A1 (en) | 2021-06-10 | 2022-12-15 | Alexander HOVARD SPARRE-ULRICH | Treatment of obesity and obesity-related disorders |
| IL309235A (en) | 2021-06-24 | 2024-02-01 | Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd | Glp-1 receptor agonist and composition and use thereof |
| CN117715906A (zh) | 2021-07-21 | 2024-03-15 | 和博医药有限公司 | 胰高血糖素样肽-1受体调节剂及其用途 |
| CN113480534B (zh) | 2021-07-23 | 2022-05-13 | 广州必贝特医药股份有限公司 | 苯并咪唑或氮杂苯并咪唑-6-羧酸类化合物及其应用 |
| WO2023011539A1 (zh) | 2021-08-04 | 2023-02-09 | 上海翰森生物医药科技有限公司 | 环烯类衍生物调节剂、其制备方法和应用 |
| WO2023016546A1 (en) | 2021-08-12 | 2023-02-16 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| KR20240099142A (ko) | 2021-08-27 | 2024-06-28 | 버사니스 바이오, 인크. | 병용 요법 |
| WO2023029380A1 (zh) | 2021-08-30 | 2023-03-09 | 杭州德睿智药科技有限公司 | 作为glp1r激动剂的新型芳醚取代杂环类化合物 |
| CA3230347A1 (en) | 2021-08-31 | 2023-03-09 | Pfizer Inc. | Solid forms of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt |
| US20240374587A1 (en) | 2021-09-08 | 2024-11-14 | Shionogi & Co., Ltd. | Medicine for prevention and treatment of diseases linked to anti-obesity activity |
| PT4408840T (pt) | 2021-09-27 | 2025-10-07 | Terns Pharmaceuticals Inc | Ácidos benzimidazolocarboxílicos como agonistas de glp-1r |
| US20250115612A1 (en) | 2021-10-05 | 2025-04-10 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4-b]pyrazines as glp-1 receptor modulators |
| WO2023057414A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
| MX2024004131A (es) | 2021-10-05 | 2024-04-22 | Astrazeneca Ab | Ciertos 2,5-diazabiciclo[4.2.0]octanos como moduladores del receptor de glp-1. |
| TWI843243B (zh) | 2021-10-22 | 2024-05-21 | 大陸商盛世泰科生物醫藥技術（蘇州）股份有限公司 | 作為glp-1受體激動劑的化合物、包含其的藥物組成物及其用途 |
| CN118401519A (zh) * | 2021-10-25 | 2024-07-26 | 拓臻制药公司 | 作为glp-1r激动剂的化合物 |
| JPWO2023106310A1 (https=) | 2021-12-07 | 2023-06-15 | ||
| CN114280573B (zh) | 2021-12-09 | 2025-09-26 | 上海禾赛科技有限公司 | 激光雷达及其测量目标反射率的方法和系统 |
| US20250042882A1 (en) | 2021-12-16 | 2025-02-06 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| WO2023111144A1 (en) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| WO2023124824A1 (zh) | 2021-12-29 | 2023-07-06 | 海思科医药集团股份有限公司 | 一种glp-1激动剂的盐及其晶型和在医药上的应用 |
| EP4469444A4 (en) | 2022-01-24 | 2026-01-07 | Gasherbrum Bio Inc | GLP-1 HETEROCYCLIC AGONISTS |
| JP2025506474A (ja) | 2022-02-09 | 2025-03-11 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環ｇｌｐ－１アゴニスト |
| US20250177362A1 (en) | 2022-02-09 | 2025-06-05 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| EP4476212A1 (en) | 2022-02-10 | 2024-12-18 | Novartis AG | 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity |
| CN119095843A (zh) | 2022-02-23 | 2024-12-06 | 拓臻制药公司 | 作为glp-1r激动剂的化合物 |
| AU2023225875A1 (en) | 2022-02-28 | 2024-09-26 | Ascletis Bioscience Co., Ltd. | Glp-1r modulating compounds |
| JP2025509281A (ja) | 2022-03-09 | 2025-04-11 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環式ｇｌｐ－１アゴニスト |
| US20250206757A1 (en) | 2022-03-21 | 2025-06-26 | Gasherbrum Bio, Inc. | 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes |
| US20250250269A1 (en) | 2022-04-14 | 2025-08-07 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| US20250136584A1 (en) | 2022-05-20 | 2025-05-01 | Chengdu Di'ao Jiuhong Pharmaceutical Factory | Benzimidazole Or Azabenzimidazole Compound, Preparation Method Therefor And Use Thereof |
| CN114716423A (zh) | 2022-05-20 | 2022-07-08 | 中国科学院上海药物研究所 | 5,6-二氢-1,2,4-三嗪类化合物及其作为glp-1受体激动剂的药学用途 |
| CN120379988A (zh) | 2022-08-24 | 2025-07-25 | 广州市联瑞制药有限公司 | 苯并双环类化合物及其制备方法和应用 |
| CN119894885A (zh) | 2022-08-30 | 2025-04-25 | 广州市联瑞制药有限公司 | 苯并双环类化合物及其制备方法和应用 |
| WO2024051700A1 (zh) | 2022-09-05 | 2024-03-14 | 德睿智药(苏州)新药研发有限公司 | 作为glp1r激动剂的新型芳基氘代苄醚取代杂环类化合物 |
| EP4592285A1 (en) | 2022-09-22 | 2025-07-30 | Shionogi & Co., Ltd. | Fused ring compound having glp-1 receptor agonist effect |
| JPWO2024063140A1 (https=) | 2022-09-22 | 2024-03-28 | ||
| WO2024102625A1 (en) | 2022-11-11 | 2024-05-16 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
| KR20250085816A (ko) | 2022-11-16 | 2025-06-12 | 일라이 릴리 앤드 캄파니 | 글루카곤-유사 펩티드 1 수용체 효능제 |
| WO2024131869A1 (en) | 2022-12-22 | 2024-06-27 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| JP2026500865A (ja) | 2023-01-13 | 2026-01-08 | 中国科学院上海薬物研究所 | Ｇｌｐ－１受容体アゴニストとして使用される４－アルコキシベンゾイミダゾール－６－カルボン酸誘導体 |
| US20240368120A1 (en) | 2023-03-29 | 2024-11-07 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| TW202504595A (zh) | 2023-03-29 | 2025-02-01 | 美商拓臻製藥公司 | Ｇｌｐ—１ｒ促效劑之多晶型及鹽 |
-
2022
- 2022-09-27 PT PT227930369T patent/PT4408840T/pt unknown
- 2022-09-27 CN CN202280076014.4A patent/CN118251391A/zh active Pending
- 2022-09-27 HU HUE22793036A patent/HUE073500T2/hu unknown
- 2022-09-27 EP EP22793036.9A patent/EP4408840B1/en active Active
- 2022-09-27 US US17/954,047 patent/US20230150998A1/en not_active Abandoned
- 2022-09-27 LT LTEPPCT/US2022/044915T patent/LT4408840T/lt unknown
- 2022-09-27 MX MX2024003872A patent/MX2024003872A/es unknown
- 2022-09-27 ES ES22793036T patent/ES3049198T3/es active Active
- 2022-09-27 AU AU2022349020A patent/AU2022349020A1/en active Pending
- 2022-09-27 RS RS20250985A patent/RS67271B1/sr unknown
- 2022-09-27 PE PE2024000596A patent/PE20241130A1/es unknown
- 2022-09-27 HR HRP20251161TT patent/HRP20251161T1/hr unknown
- 2022-09-27 KR KR1020247014116A patent/KR20240068737A/ko not_active Withdrawn
- 2022-09-27 WO PCT/US2022/044915 patent/WO2023049518A1/en not_active Ceased
- 2022-09-27 DK DK22793036.9T patent/DK4408840T3/da active
- 2022-09-27 IL IL311667A patent/IL311667A/en unknown
- 2022-09-27 FI FIEP22793036.9T patent/FI4408840T3/fi active
- 2022-09-27 SI SI202230182T patent/SI4408840T1/sl unknown
- 2022-09-27 EP EP24211557.4A patent/EP4537899A3/en active Pending
- 2022-09-27 CA CA3233201A patent/CA3233201A1/en active Pending
- 2022-09-27 JP JP2024518821A patent/JP2024534621A/ja not_active Withdrawn
- 2022-09-27 TW TW111136613A patent/TW202322806A/zh unknown
- 2022-09-27 PL PL22793036.9T patent/PL4408840T3/pl unknown
- 2022-09-27 SM SM20250374T patent/SMT202500374T1/it unknown
-
2024
- 2024-03-25 CL CL2024000861A patent/CL2024000861A1/es unknown
- 2024-04-22 CO CONC2024/0005060A patent/CO2024005060A2/es unknown
- 2024-11-22 US US18/956,385 patent/US20250282772A1/en active Pending
-
2025
- 2025-01-13 US US19/018,788 patent/US12378238B2/en active Active
- 2025-01-13 US US19/018,754 patent/US12378236B2/en active Active
- 2025-01-13 US US19/018,773 patent/US12378237B2/en active Active
- 2025-01-13 US US19/018,805 patent/US12522596B2/en active Active
- 2025-01-13 US US19/018,817 patent/US12378239B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20240068737A (ko) | Glp-1r 효능제로서의 벤즈이미다졸 카복실산 | |
| US12410163B2 (en) | Compounds as GLP-IR agonists | |
| US12024507B2 (en) | Compounds as GLP-1R agonists | |
| WO2022109182A9 (en) | Polyheterocyclic glp-1 r modulating compounds | |
| CN119977993A (zh) | 噻吩并嘧啶二酮acc抑制剂的固体形式及其制备方法 | |
| HK40115043A (en) | Benzimidazole carboxylic acids as glp-1r agonists | |
| HK40115043B (en) | Benzimidazole carboxylic acids as glp-1r agonists | |
| HK40113150A (zh) | 作为glp-1r激动剂的苯并咪唑羧酸 | |
| HK40055242A (zh) | 噻吩并嘧啶二酮acc抑制剂的固体形式及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| B11 | Application withdrawn |
Free format text: ST27 STATUS EVENT CODE: N-1-6-B10-B11-NAP-PC1202 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PC1202 | Submission of document of withdrawal before decision of registration |
St.27 status event code: N-1-6-B10-B11-nap-PC1202 |